Tag:

biotech VC

Latest Headlines

Latest Headlines

Naurex bags an $80M round for PhIII study of an NMDA drug for depression

Whatever data Naurex collected from its recently completed Phase IIb study of an NMDA receptor drug for depression, it must have deeply impressed its investment syndicate. Today the company unveiled the news that it has rounded up an $80 million round designed to put the drug through a late-stage pivotal trial.

Price of UniQure gene therapy tops €1.1M, fund backs RET inhibitors, Promethera bags €25M

Welcome to the latest edition of our weekly EuroBiotech Report.

Report: Woodford is diving full on into biotech with new $314M fund

High-profile U.K. investor Neil Woodford made headlines last week when he invested $25 million into Northwest Biotherapeutics, and that's a sign of much more to come, according to reports, as the ex-Invesco manager is planning to unveil a new fund devoted solely to emerging biotechs.

What's the #1 biotech hub for VCs? (It's still not Boston)

Biotech investing is sizzling right now, and despite all the attention that the Boston hub gets, the Bay Area is still number one.

Thinking 'big,' Arch Venture gathers $400M-plus to back a new wave of biotechs

Arch Venture Partners has joined a lineup of top venture groups which has been making hay while the market sun shines on biotech IPOs. The VC has marshaled more than $400 million for its new investment fund--its eighth--that will now be available to back a new wave of cutting-edge life science companies, often starting from scratch.

Dermira pockets $51M to bankroll skin treatments

Well-funded biotech Dermira has landed a $51 million C round to support its late-stage dermatology pipeline, rallying some high-profile investors as it dials up R&D spending and builds out its management team.

Venrock unveils a $450M new fund with eyes on biotech

Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.

Big Pharma is using its venture cash to outsource early R&D to biotech

Analysts at Silicon Valley Bank have been crunching the numbers on biotech investing, and they have found that a group of busy corporate venture arms has fundamentally changed the landscape for startups and the entire field of early-state drug development--with some big implications for the current crop of industry upstarts.

Sofinnova closes $500M venture fund, keeps late-stage focus

Sofinnova Ventures has evolved rapidly over the past decade to suit the times, from a diversified early stage biotech and IT investor to focusing solely on later stage biotech. And LPs seem to think it is making all the right moves; it has closed a ninth fund at $500 million, the hard cap for the fund that was initially targeting $425 million.

New Science Ventures joins the biotech VC boom, plots $100M fund

With investors revved up about biotech's future, a string of funds have outlined plans to raise billions of dollars to back a new generation of life science companies. And New Science Ventures is joining the frenzy with a $100 million game plan of its own.